Select Page

The Center for Cancer Research (CCR) of the National Cancer Institute (NCI)/NIH, headed by Dr. Dimiter S. Dimitrov, and SNBL USA recently conducted a pharmacokinetic study with a bispecific monoclonal antibody targeting a cancer-related protein, IGF2.The results serve as a basis for further investigations which could lead to novel approaches for therapy of tumors that have this specific protein.To link to the website

A new bispecific antibody targeting non-overlapping epitopes on IGF2: Design, in vitro characterization and pharmacokinetics in macaques.

The Protein Interactions Section of the Cancer and Inflammation Program (CIP) at the Center for Cancer Research (CCR) of the National Cancer Institute (NCI)/NIH, headed by Dr. Dimiter S. Dimitrov, and SNBL USA recently conducted a pharmacokinetic study in macaques with a bispecific monoclonal antibody targeting a cancer-related protein, IGF2. The experiment was designed to test a novel hypothesis regarding the irreversible removal of IGF2 from the circulation. The data obtained allowed Dr. Dimitrov’s team to calculate the elimination half-life of the antibody, however, there was no effect on the IGF2 concentration in the blood. This study will serve as a basis for further investigations which could lead to novel approaches for various tumor therapies. The goal of Dr. Dimitrov’s research, as a whole, is to focus on the development of clinically useful therapeutics and vaccines against cancer, HIV-1 and emerging viruses as well as other related diseases including immune disorders. They are based on human monoclonal antibodies in several formats and could make real differences in our lives.

For the complete abstract, see the following link to PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25220345